Agfa unveils data center at HIMSS 2007Grid developer expands reach, portfolioConfirma bolsters CAD softwareHologic supplies CADS to U.S. Army Misys adds billing softwareImaging firm bags DoD contractiCAD recruits exec for European ops Radlink names chief marketing officerPACS offers bone measurement
For the first time, data accrued over a decade show that the involvement of the pharmaceutical industry in clinical breast cancer research may have significantly influenced study design, focus, and results, according to a study published in the April 1 issue of Cancer.
Breast ultrasound is a highly useful tool in the hands of an expert, but it is notoriously operator-dependent. Systems that offer partial or full automation to minimize performance variability are gaining attention, as trial data accumulate and system designs evolve.
Men treated for breast cancer face a significantly high risk of future cancers, according to a study published online in the January issue of Breast Cancer Research. The data validate previous findings and suggest a role for screening in these patients.
Kodak’s Health Group begins transition to ‘Carestream’Hologic notches record quarterKorean LCDs include Matrox controllersRIS/PACS firm raises $3.3M
Use of breast ultrasound and MRI in Medicare beneficiaries has been on the rise in a big way, but the picture of mammography utilization in this patient population is less rosy.
The thrust for Richland, WA-based Advanced Imaging Technologies over the last four years has been to transform the acoustical holography system developed by its predecessor firm, Advanced Diagnostics, into a commercial product. The fruit of those labors is the company’s first product, its Aria Breast Imaging System.
Radiologists can maximize their diagnoses of lung abnormalities using computer-aided detection systems if they develop a better understanding of the strengths and shortcomings of every factor involved in the process, according to studies presented at the 2006 RSNA meeting.
News that two views are better than one with the emerging and promising technology of breast tomosynthesis raises questions about the technique's practicality and cost-effectiveness as a screening tool.
As if haunted by some kind of Ghost of Healthcare Future, the latest crop of breast imaging papers reported at the RSNA meeting conveyed an ominous undercurrent of uncertainty.
Epix scores with GSK allianceSiemens ties into Fuji CR mammographyBRIT unveils multimodality mammography workstation
Toshiba spotlights CT workflowChina pays for optical mammographyKodak, NDMA ally in Europe
Viatronix merges CAD, virtual colonographyReview of DMIST exposes downside of digital mammographyAurora Imaging heads for China AllRad strikes deal with national PPO
Full-field digital mammography yields higher cancer detection rates than conventional mammography but also boosts recall rates, according to large European studies involving thousands of women. Study findings were presented at the RSNA meeting last week.
The validity of population-based breast screening has once again been called into question by the world's media. The negative headlines have, ironically, been triggered by a report that finds mammography screening saves lives. But it is the concurrent likelihood of overdiagnosis that has captured journalists' attention.
Molecular imaging is maturing as a scientific force in preclinical research and as a mechanism to guide imaging discoveries toward clinical practice.
Full-field digital mammography yields higher cancer detection and recall rates than conventional mammography, based on large European studies involving thousands of women. Study findings were presented at the RSNA meeting Tuesday.
News that two views are better than one with the emerging and promising technology of breast tomosynthesis raises questions about the technique’s practicality and cost-effectiveness as a screening tool.
Computed radiography arrived at the RSNA meeting Sunday ready for sale into the U.S. market as a mammography application. At the head of the pack was Fujifilm Medical Systems USA, the only vendor with FDA approval to sell CR for mammography. It received the agency green light in July.
New analyses of data from the Digital Mammographic Imaging Screening Trial show that digital mammography is superior only for pre- and perimenopausal women with dense breasts. Screen-film mammography may actually have an edge in older women with fatty breasts, according to a study presented at the RSNA meeting on Sunday.
Computed radiography arrived at the RSNA meeting Sunday ready for sale into the U.S. market as a mammography application. At the head of the pack was Fujifilm Medical Systems USA, the only vendor with FDA approval to sell CR for mammography. It received the agency green light in July.
New analyses of data from the Digital Mammographic Imaging Screening Trial show that digital mammography is superior only for pre- and perimenopausal women with dense breasts. Screen-film mammography may actually have an edge in older women with fatty breasts, according to a study presented at the RSNA meeting on Sunday.
There are two ways into the U.S. market for computed radiography for mammography. One path, successfully traversed by FujiFilm Medical Systems USA and now being trod by Kodak, is the FDA's premarket approval (PMA) process. But Konica Minolta is taking the road less traveled.
iCAD readies RSNA exhibitsUltraRad offers free offsite archivingSiemens snags $40M dealGE expands alliance with Intermountain
Kodak will showcase its computed radiography platform for mammography at the RSNA meeting, but it will have to do so as a work-in-progress, at least for customers in the U.S.
